Clinical Considerations for <em>RET</em> Fusion–Positive NSCLC

Decera Clinical Education Oncology Podcast · Sep 17, 2020 · 24m

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:

Optimal testing for RET fusions

DNA NGS vs RNA NGS

Molecular testing workflows

Using new selective RET inhibitors to treat patients with RET fusion–positive NSCLC

Common toxicities with new selective RET inhibitors

Interdisciplinary communication between medical oncologists and pathologists

Presenters:

Dara L. Aisner, MD, PhD

Associate Professor…